Introduction ! Advancements of breast cancer treatment and prevention have emerged over the last decade. The developments in both fields imply that both breast cancer treatment and breast cancer risk assessment have to develop towards each other. Concerning breast cancer treatment and prognostic assessment the implementation and understanding of molecular subgroups has changed the approach how to treat breast cancer fundamentally [1] [2] [3] . It has been learnt that molecular subgroups of breast cancer represent either genetic or otherwise unique molecular patterns that determine the prognosis and seem to be the consequence of a specific pathogenesis [4] . With regard to breast cancer risk research the formation of large scale international networks with tens of thousands of breast cancer patients and controls with available genetic and non-genetic Abstract ! Several advancements over the last decade have triggered the developments in the field of breast cancer risk research. One of them is the availability of the human genome sequence along with cheap genotyping possibilities. Another is the globalization of research, which has led to the growth of research collaboration into large international consortia that facilitate the pooling of clinical and genotype data of hundreds of thousands of patients and healthy control individuals. This review concerns with the recent developments in breast cancer risk research and focuses on the discovery of new genetic breast cancer risk factors and their meaning in the context of established non-genetic risk factors. Finally the clinical application is highly dependent on the accuracy of breast cancer risk prediction models, not only for all breast cancer patients, but also for molecular subtypes, preferably for those which are associated with an unfavorable prognosis. Recently risk prediction incorporates all possible risk factors, which include epidemiological risk factors, mammographic density and genetic risk factors.
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Zusammenfassung

Genetic Risk Factors
!
Since the discovery of the breast cancer genes 1 and 2 (BRCA1 and BRCA2) in 1994 and 1995 [5, 6] many genetic variants have been described to contribute to breast cancer risk. After years of candidate gene research with its problems concerning false positive reporting [7] large consortia have enabled research at a genome-wide level, discovering and validating genetic variants that are associated with breast cancer risk. These genetic, inheritable variants are the reason for familial breast cancer risk. While higher penetrant loci make up for about 20 % of familial breast cancer risk, about 28 % are explained by newly discovered low penetrant loci, of which 14 % are explained by about 70 low penetrant loci [8] .
Recently more than 45 new common genetic breast cancer susceptibility loci were identified [8] . The following section will describe the discovery of those low penetrant loci, as this effort demonstrated the kind of collaborative efforts that lead to such success. In order to facilitate large scale genotyping the multicenter Collaborative Oncological Gene-environment Study (COGS) was founded aiming at the discovery of genetic factors of three hormone-related cancer types (breast, ovarian and prostate cancer), represented by several consortia, BCAC (Breast Cancer Association Consortium), CIMBA (The Consortium of Investigators of Modifiers of BRCA1/2), OCAC (Ovarian Cancer Association Consortium) and PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome). For further information see www.cogseu.org. These consortia built a custom genotyping array with more than 200 000 SNPs (iCOGS Chip), which was used for germline DNA genotyping of more than 200 000 individuals. SNPs that were tested for breast cancer risk as part of COGS were selected from genome-wide association studies, performed in more than 10 000 breast cancer cases and more than 12 500 controls. Almost 30 000 SNPs were re-genotyped in more than 45 000 breast cancer cases and almost 42 000 healthy controls. This study identified more than 45 new breast cancer risk genetic variants [8] [9] [10] additionally to already published SNPs. An overview of validated breast cancer risk SNPs over the last decade is given in l " Table 1 . Besides these validated breast cancer SNPs, that explain about 14 % of familial breast cancer risk, it is suggested that about 1000 additional loci are involved in breast cancer susceptibility [8] .
SNPs and Disease Risk Modification in BCRA Mutation Carriers
!
The same collaborative group was used to discover and validate genetic risk modifiers for individuals with a BRCA mutation [11] . The CIMBA within COGS used a genome-wide association study in more than 2700 BRCA1 mutation carriers and selected about 32 000 SNPs to be genotyped with the iCOGS chip. A total of 11 705 BRCA1 mutation carriers were genotyped with the iCOGS chip. This analysis gave indication that 17 SNPs were of interest and were genotyped in further about 2500 BRCA1 mutation carriers [11] . After analysis for breast and ovarian cancer risk in this specific population, a novel breast cancer risk modifier locus at 1q32 for BRCA1 mutation carriers was described (rs2290854, HR = 1.14, 95 % CI: 1.09, 1.20). Two further SNPs were associated with ovarian cancer risk, one locus at 17q21.31 (rs17631303, HR = 1.27, 95% CI: 1.17, 1.38) and one at 4q32.3 (rs4691139, HR = 1.20, 95 % CI: 1.17-1.38). Previously described risk modifiers and this new locus are summarized in l " Table 2 . When modeling breast cancer lifetime risk for BRCA1 mutation carriers it becomes clear that additional loci can help to estimate different lifetime risks substantially more accurate. In this model BRCA1 mutation carriers have an average lifetime risk of about 65 % (l " Fig. 1 from [11] ). When incorporating genetic variants from 10 additional genes into the lifetime risk calculation of BRCA1 mutation carriers [9, 11] it can be seen that at the 5 % and 95 % percentiles of the population, lifetime risks of about 80% and 50 % can be calculated. At the rare maximum and minimum level risks, even almost 100 % and about 30 % lifetime risk are calculated, however these constellations are very rare.
Pathways for triple negative breast cancers
It has been known already for some time, that BRCA mutations occur more frequently in patients with triple negative breast cancer tumors. This implies that the missing function of BRCA during the pathogenesis of breast cancer ultimatively leads to a triple negative breast cancer. In unselected cases the frequency of BRCA mutations among triple negative breast cancer patients has been reported to range between 4 and 21 % (l " Table 3 ), however all populations were rather small and the study with the highest reported BRCA mutation prevalence included some familial cases. Other rare and medium to high penetrant mutations are dis- cussed to be associated with triple negative breast cancers such as RAD51, TP53, BRAF, KRAS and others [12, 13] . Besides these high penetrant genes there are several common variants that have been associated with a triple negative pathogenesis of breast cancer [14] . There have been reports about genetic variants in the following genes or regions to be associated with triple negative breast cancer risk: TERT, MDM4, 19p13.1 [10, 15, 16] . Additionally some loci were specific for estrogen receptor negative tumors and not estrogen receptor positive tumors. These loci are FTO, LGR6, RALY and 2p24.1 [10, 17] .
Age
Non-Genetic Risk Factors and Molecular Mechanism of Pathogenesis
!
Only few non-genetic risk factors can be linked to a specific mechanism of action, such as DNA damage by radiation or some chemicals. For most non-genetic risk factors the molecular mechanism of action is unclear. However during the last years some studies have been published that shed some light on the pathogenesis of non-genetic risk factors. These studies explore whether breast cancer risk factors are specifically modifying the risk for intrinsic subtypes of breast cancer. Others studies inves- tigate the interaction between molecular mechanisms of pathogenesis and risk factors. Finally interactions between commonly established risk factors and genetic risk factors could help as well to acquire knowledge about the molecular pathogenesis of nongenetic risk factors.
Pregnancies and breastfeeding
Pregnancies and breastfeeding are thought to have two effects on a womanʼs breast cancer risk. During and shortly after pregnancy, women have an increased risk of breast cancer, but later in life the breast cancer risk is lower in comparison with women who have never given birth to a child [18] . Most studies use a design that examines women at a later stage of their life cycle and provides data on the risk-reducing effect. Women with no live deliveries have a lifetime risk of about 6.3 % up to the age of 70 [19] . The risk decreases with each pregnancy. The relative risk of breast cancer decreases by 4.3 % (95 % CI, 2.9 to 5.8) for every 12 months of breastfeeding, in addition to a decrease of 7.0 % (95 % CI, 5.0 to 9.0) for each birth [19] .
There is some evidence that nulliparity and increasing age at first birth are associated with an increased risk for estrogen receptor positive breast cancer as well as progesterone receptor positive breast cancer, but not for triple negative breast cancer [20] . Similar associations are seen in case-case analyses. Patients with ER negative tumors are more likely to be nulliparous or having a high age at first birth [20] . The molecular mechanisms that link non-genetic risk factors to the pathogenesis of breast cancer are mainly unknown, however some first insights have been found in studies that look at the interaction between non-genetic and genetic risk factors with regard to breast cancer risk. A study within the COGS examined the interaction between 10 established environmental risk factors and 23 SNPs [21] . This study could show that the effect of rs3817198 in LSP1 (Lymphocyte-specific protein 1) is greater in women with more births [21] . LSP1 is expressed in white blood cells and has been described to regulate neutrophil motility and adhesion to extracellular matrix proteins [22] . However it has to be pointed out that these kind of interaction analyses require really large sample sizes and a well-performed quality control of genotype and clinical data, as earlier studies with a smaller sample size (26 000 cases and 32 000 controls) were not able to show this LSP1-association after adjustment for multiple testing, although the nominal p-value for this association was 0.002 [23] .
Mammographic density
Mammographic density (MD) is one of the most important risk factors for breast cancer. Women with a high MD have an up to fivefold increase in the risk for breast cancer [24] [25] [26] . Because of its importance, knowledge about the molecular mechanisms, and how mammographic density is linked to breast cancer pathogenesis, could be of special use for breast cancer prevention. Some studies investigated whether mammographic density is a risk factor for a certain type of cancer. Early studies have shown that, for example, tumor histology was associated with breast cancer risk [27] . In a recent case-control study mammographic density seemed to be a stronger risk factor for cancer with a higher grading and estrogen receptor negative breast cancer. These results were confirmed in a case-case analysis associating a higher mammographic density with a lower percentage of estrogen receptor positive tumors [28] . The same study implied that the association with progesterone receptor positivity was inverse to that with the estrogen receptor. The authors concluded that mammographic density could specifically increase breast cancer risk through the progesterone receptor pathway, possibly involving RANK and RANKL [28] .
The same case-case study did not see an association between mammographic density and tumor proliferation as assessed by Ki-67, however the association of commonly known breast cancer risk factors with mammographic density was different in patients with a high and a low proliferative tumor [29] , suggesting that there might be a more complex relation between several risk factors and breast cancer pathogenesis.
Recently it could be shown on the protein level that the surface protein CD36 might be the mediator, which is responsible for high mammographic density in both healthy breast tissue and breast tumors [30] . It was shown that CD36 induces the transformation of stromal cells to adipocytes and that it suppressed the expression of extracellular matrix proteins. This was seen in both healthy breast tissue and tumor tissue [30] . This work is one of the first to shed light on the molecular background of breast density regulation in healthy and malignant tissue. Finally there have been genetic risk factors that could be associated with several risk factors for breast cancer and breast cancer risk itself. One of these examples is the SNP rs3817198 in the gene LSP1. The rare allele was associated with both, a higher breast cancer risk and a higher mammographic density [31] . The same was seen for rs10483813 in RAD51L1 [31] . The SNP in LSP1 seems to be of special interest for breast cancer as it does not only alter breast cancer risk, is interacting with parity and mammographic density as breast cancer risk factors, but has been described as a prognostic factor in hormone receptor breast cancer patients as well [32] . These findings are some of the first examples that can help to understand through which molecular pathways breast density is linked to the pathogenesis of breast cancer. It will need more comprehensive analyses to identify further molecules and pathways that help to understand those connections.
Breast Cancer Assessment in Practice
!
The information available about breast cancer risk has now become truly comprehensive. It has been applied in practice in the large breast cancer prevention trials, selecting for women with an increased risk for breast cancer, but the use of breast cancer risk assessment tools in clinical practice appears to be limited with regard to all aspects of prevention, intensified early detection, prophylactic medication, and prophylactic surgery. Several tools have been developed for assessing breast cancer risk; some of the most frequently used are summarized in l " Table 4 in relation to their use of risk factor information [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . Some have been in use for decades already, such the Gail model [41] . More recently developed risk models aim at the combination of several risk factors, specifically mammographic density and genetic risk factors. The Tice model was one of the first to include mammographic density [44] . Together with genetic risk factors these models will possibly improve with regard to clinical utility. A case-control study has already combined breast density, breast cancer risk SNPs and clinical risk factors for the prediction of breast cancer risk [43] . Models for breast cancer risk prediction do not at present distinguish between distinct molecular subtypes, although subtypespecific risk factors have already been identified [20, [45] [46] [47] [48] [49] .
However, predicting breast cancer and assessing specific risks can only make sense if they address women who have a high likelihood of developing a cancer with an unfavorable prognosis [50] .
As early detection and cancer treatment also have an impact on survival, studies would ideally have to be designed in order to predict which women are likely to have an aggressive tumor that can be detected early [50] .
Conclusions
!
Large international consortia and large scale genotyping studies can help to systematically work on the molecular background of breast cancer etiology and ultimately shed light on how these risk factors are connected to the pathogenesis on the molecular level. Over the last few years, very first insights have been described how non-genetic risk factors are linked to breast cancer risk on the molecular level. The scarceness of data that link breast cancer risk factors to molecular pathways of the pathogenesis makes clear that many more efforts have to be made in the future to elucidate these important causal links. However the plenty of new risk factors on the genetic side promise the discovery of new connections in the network of breast cancer risk factors. 
